Danish drugmaker Lundbeck has announced the availability of ONFI (clobazam) in scored tablet and oral suspension formulations in the US pharmacies beginning this week.
ONFI, an oral anti-epileptic drug (AED) of the benzodiazepine class, is a federally controlled schedule four substance (CIV).
Originally approved by the FDA in 2011, ONFI is a prescription medication used along with other medicines to treat seizures associated with Lennox-Gastaut syndrome (LGS) in adults and children two years of age or older.
The new oval shaped ONFI Scored Tablets (10mg and 20mg), which will replace the previously available round non-scored tablets, contain the same ingredients as the round tablet, and include a functional score to allow patients or their caregivers to split the tablets in half.
While ONFI will no longer be available in a 5mg tablet, ONFI Oral Suspension (2.5mg/ml) has a berry flavor, and provides an alternative to ONFI tablets.
Lundbeck US ONFI marketing director Mike Hanley said that the availability of the new formulations is the result of working closely with the LGS community and based on the feedback from physicians, patients and caregivers.
"We are inspired by the strength of those impacted by LGS and will continue working together to help these patients and their families," Hanley added.